Sacituzumab govitecan (Trodelvy) now has regular FDA approval for people with locally advanced or metastatic triple-negative breast cancer (TNBC), including those with brain metastases. The update follows last year’s accelerated approval of the drug for people with TNBC.
EX-99.2
Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer
Another Player in Advanced Bladder Cancer
Kevin Punie on X: #ESMO21 Sacituzumab govitecan is a major
Sacituzumab Earns Regular FDA Approval For TNBC NCI
Frontiers Immunotherapy in triple-negative breast cancer
Mission Mountain Wilderness
Pharmaceutics, Free Full-Text
Mission Mountain Wilderness